Logo image of CRVO

CERVOMED INC (CRVO) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:CRVO - US15713L1098 - Common Stock

7.28 USD
+0.2 (+2.82%)
Last: 1/16/2026, 8:02:57 PM
7.28 USD
0 (0%)
After Hours: 1/16/2026, 8:02:57 PM
Fundamental Rating

3

CRVO gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 525 industry peers in the Biotechnology industry. CRVO has a great financial health rating, but its profitability evaluates not so good. CRVO does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • In the past year CRVO has reported negative net income.
  • CRVO had a negative operating cash flow in the past year.
  • CRVO had negative earnings in each of the past 5 years.
  • In the past 5 years CRVO always reported negative operating cash flow.
CRVO Yearly Net Income VS EBIT VS OCF VS FCFCRVO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M -20M -25M

1.2 Ratios

  • With a Return On Assets value of -83.58%, CRVO is not doing good in the industry: 69.43% of the companies in the same industry are doing better.
  • CRVO has a Return On Equity of -98.36%. This is comparable to the rest of the industry: CRVO outperforms 46.42% of its industry peers.
Industry RankSector Rank
ROA -83.58%
ROE -98.36%
ROIC N/A
ROA(3y)-42.82%
ROA(5y)-50.07%
ROE(3y)-49.37%
ROE(5y)-56.44%
ROIC(3y)N/A
ROIC(5y)N/A
CRVO Yearly ROA, ROE, ROICCRVO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150

1.3 Margins

  • CRVO does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CRVO Yearly Profit, Operating, Gross MarginsCRVO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150

More info and screens

7

2. Health

2.1 Basic Checks

  • The number of shares outstanding for CRVO has been increased compared to 1 year ago.
  • The number of shares outstanding for CRVO has been increased compared to 5 years ago.
  • There is no outstanding debt for CRVO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
CRVO Yearly Shares OutstandingCRVO Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M
CRVO Yearly Total Debt VS Total AssetsCRVO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

2.2 Solvency

  • CRVO has an Altman-Z score of 2.97. This is not the best score and indicates that CRVO is in the grey zone with still only limited risk for bankruptcy at the moment.
  • CRVO has a Altman-Z score of 2.97. This is in the better half of the industry: CRVO outperforms 68.49% of its industry peers.
  • There is no outstanding debt for CRVO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 2.97
ROIC/WACCN/A
WACCN/A
CRVO Yearly LT Debt VS Equity VS FCFCRVO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M 30M

2.3 Liquidity

  • A Current Ratio of 6.66 indicates that CRVO has no problem at all paying its short term obligations.
  • With a decent Current ratio value of 6.66, CRVO is doing good in the industry, outperforming 68.11% of the companies in the same industry.
  • A Quick Ratio of 6.66 indicates that CRVO has no problem at all paying its short term obligations.
  • The Quick ratio of CRVO (6.66) is better than 68.68% of its industry peers.
Industry RankSector Rank
Current Ratio 6.66
Quick Ratio 6.66
CRVO Yearly Current Assets VS Current LiabilitesCRVO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

More info and screens

3

3. Growth

3.1 Past

  • The earnings per share for CRVO have decreased strongly by -80.12% in the last year.
  • The Revenue for CRVO has decreased by -38.81% in the past year. This is quite bad
EPS 1Y (TTM)-80.12%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-52.73%
Revenue 1Y (TTM)-38.81%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-83.37%

3.2 Future

  • The Earnings Per Share is expected to grow by 10.47% on average over the next years. This is quite good.
  • Based on estimates for the next years, CRVO will show a very strong growth in Revenue. The Revenue will grow by 43.66% on average per year.
EPS Next Y-34.74%
EPS Next 2Y2.4%
EPS Next 3Y8.48%
EPS Next 5Y10.47%
Revenue Next Year-47.93%
Revenue Next 2Y-69.28%
Revenue Next 3Y-25.99%
Revenue Next 5Y43.66%

3.3 Evolution

CRVO Yearly Revenue VS EstimatesCRVO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 2025 2026 2028 2029 2030 2031 2032 2033 500M 1B 1.5B 2B 2.5B
CRVO Yearly EPS VS EstimatesCRVO Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 -500 -1K -1.5K

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for CRVO. In the last year negative earnings were reported.
  • Also next year CRVO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CRVO Price Earnings VS Forward Price EarningsCRVO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CRVO Per share dataCRVO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 -2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y2.4%
EPS Next 3Y8.48%

More info and screens

0

5. Dividend

5.1 Amount

  • CRVO does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

CERVOMED INC

NASDAQ:CRVO (1/16/2026, 8:02:57 PM)

After market: 7.28 0 (0%)

7.28

+0.2 (+2.82%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-07
Earnings (Next)03-16
Inst Owners23.45%
Inst Owner Change0.39%
Ins Owners24.03%
Ins Owner Change2.01%
Market Cap67.34M
Revenue(TTM)6.16M
Net Income(TTM)-25.58M
Analysts81.43
Price Target22.88 (214.29%)
Short Float %2.45%
Short Ratio2.19
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-7.8%
Min EPS beat(2)-8.93%
Max EPS beat(2)-6.67%
EPS beat(4)1
Avg EPS beat(4)-5.85%
Min EPS beat(4)-24.49%
Max EPS beat(4)16.71%
EPS beat(8)2
Avg EPS beat(8)-9.02%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-39.13%
Min Revenue beat(2)-77.68%
Max Revenue beat(2)-0.58%
Revenue beat(4)2
Avg Revenue beat(4)-11.94%
Min Revenue beat(4)-77.68%
Max Revenue beat(4)21.32%
Revenue beat(8)5
Avg Revenue beat(8)6.67%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)17.16%
EPS NQ rev (1m)-9.54%
EPS NQ rev (3m)-21.09%
EPS NY rev (1m)-2.43%
EPS NY rev (3m)-15.76%
Revenue NQ rev (1m)-16.65%
Revenue NQ rev (3m)-26.58%
Revenue NY rev (1m)-3.74%
Revenue NY rev (3m)-22.66%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 10.93
P/FCF N/A
P/OCF N/A
P/B 2.59
P/tB 2.59
EV/EBITDA N/A
EPS(TTM)-2.9
EYN/A
EPS(NY)-1.93
Fwd EYN/A
FCF(TTM)-2.69
FCFYN/A
OCF(TTM)-2.69
OCFYN/A
SpS0.67
BVpS2.81
TBVpS2.81
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -83.58%
ROE -98.36%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-42.82%
ROA(5y)-50.07%
ROE(3y)-49.37%
ROE(5y)-56.44%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.2
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.66
Quick Ratio 6.66
Altman-Z 2.97
F-Score2
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-80.12%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-52.73%
EPS Next Y-34.74%
EPS Next 2Y2.4%
EPS Next 3Y8.48%
EPS Next 5Y10.47%
Revenue 1Y (TTM)-38.81%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-83.37%
Revenue Next Year-47.93%
Revenue Next 2Y-69.28%
Revenue Next 3Y-25.99%
Revenue Next 5Y43.66%
EBIT growth 1Y-114.77%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-67.9%
EBIT Next 3Y-64.22%
EBIT Next 5Y-24.41%
FCF growth 1Y-197.44%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-197.44%
OCF growth 3YN/A
OCF growth 5YN/A

CERVOMED INC / CRVO FAQ

What is the fundamental rating for CRVO stock?

ChartMill assigns a fundamental rating of 3 / 10 to CRVO.


Can you provide the valuation status for CERVOMED INC?

ChartMill assigns a valuation rating of 0 / 10 to CERVOMED INC (CRVO). This can be considered as Overvalued.


What is the profitability of CRVO stock?

CERVOMED INC (CRVO) has a profitability rating of 0 / 10.


Can you provide the expected EPS growth for CRVO stock?

The Earnings per Share (EPS) of CERVOMED INC (CRVO) is expected to decline by -34.74% in the next year.